Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?

Novo Nordisk ADSes fell nearly 8% after CEO Mike Doustdar highlighted semaglutide's loss of exclusivity, with its patent-expiry cycle beginning in December 2031. Obesity-care sales still grew 26% in 2025 to DKK82 billion ($12.6 billion), representing 27% of total revenue, while Q2 obesity-drug sales increased 16% year over year. Management targets at least five multi-blockbuster launches by 2030, potentially generating more than DKK150 billion ($23 billion) in sales, and is considering M&A; however, execution risk and intensifying competition from Eli Lilly remain material.

Analysis

The market is likely to capitalize NVO's semaglutide erosion well before the first U.S. patent expiries, making the next 12-24 months a credibility test for replacement revenue rather than a 2031 event. The key variable is not the headline count of pipeline assets but whether next-generation obesity products can demonstrate superior efficacy, tolerability, dosing convenience, or cardiovascular outcomes versus LLY's incretin franchise. Without clear differentiation, NVO risks a structurally lower terminal multiple as obesity care shifts from a scarcity-driven market to one defined by formulary leverage and price competition.

LLY is the cleaner relative beneficiary: its scale, manufacturing investment, and broader late-stage obesity portfolio improve its bargaining position with PBMs and employers as coverage broadens. A less obvious beneficiary is the payer complex—UNH, CVS and CI—if competing GLP-1 suppliers use net-price concessions to secure preferred access; however, lower drug costs could be offset by higher treated-population penetration. Contract manufacturers and device suppliers face mixed effects, as oral formulations would reduce pen-injector content per patient while potentially expanding total patient volumes.

The selloff is not automatically a value signal. Management's multi-asset revenue target is aspirational until investors receive asset-level probability-adjusted sales, launch timing, and incremental R&D/capex requirements; acquisition capacity is also constrained by competition for de-risked metabolic assets. Near-term upside needs a concrete catalyst—positive pivotal data, evidence of improving U.S. prescription share, or a disciplined acquisition—while downside reopens on another guidance reset or unfavorable formulary positioning.

Contrarianly, consensus may be extrapolating competitive pressure too linearly: if capacity loosens and access expands, the obesity market can grow faster than unit-price declines, preserving meaningful cash generation through the decade. But that is a reason to own NVO only at an adequately wide valuation discount to LLY, not to underwrite pipeline targets at face value.

Key Decisions for Investors

• Maintain a 6-12 month relative-value bias: long LLY / short NVO, sized to neutralize broad GLP-1 category exposure. The trade works if LLY sustains superior prescription momentum and NVO's forward revenue or margin estimates reset; cover if NVO demonstrates sustained U.S. share stabilization plus differentiated late-stage efficacy data.
• Do not add directional NVO solely on the one-day decline. Establish an alert for the next earnings update: consider a tactical long only if management raises or reiterates obesity volume/margin guidance while net-price trends and U.S. share are independently corroborated; a further guidance cut would invalidate the value case.
• For a 12-18 month catalyst position, use defined-risk NVO call spreads only after key clinical or regulatory dates are identified. Missing inputs are implied volatility, exact trial readout dates, and consensus sales expectations; absent these, outright options are not actionable.
• Monitor PBM formulary announcements and disclosed net-price trends over the next two contracting cycles. Prefer LLY exposure if pricing concessions broaden market access without impairing gross-to-net economics; reduce both obesity longs if reimbursement expansion fails to translate into treated-patient growth.